<DOC>
	<DOCNO>NCT01511315</DOCNO>
	<brief_summary>This study aim see patient quality life approve treatment injectable medication call ustekinumab treatment generalize psoriasis . The investigator hypothesize investigator see improvement quality life .</brief_summary>
	<brief_title>The Quality Life Study Psoriasis Patients After Ustekinumab Treatment</brief_title>
	<detailed_description>The primary objective study demonstrate improvement psoriasis patient quality life 36 week ustekinumab use validate dermatologic non-dermatologic psychometric instrument .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>1 . Subjects nonimmunocompromised male females 18 year age old 2 . Subjects moderatetosevere ( ≥10 % total body surface area ) plaque psoriasis 3 . Subject diagnose least 6 month prior enter study 4 . Negative urine pregnancy test within 7 day first dose ustekinumab woman ( except surgically sterile least 5 year postmenopausal ) 5 . Sexually active subject childbearing potential must agree use medically acceptable form contraception screen throughout study . 6 . Are consider eligible accord follow tuberculosis ( TB ) screen criterion : Have history latent active TB prior screen . An exception make subject currently receive treatment latent TB evidence active TB , history latent TB documentation complete appropriate treatment latent TB within 3 year prior first administration study agent . It responsibility investigator verify adequacy previous antituberculous treatment provide appropriate documentation . Have sign symptom suggestive active TB upon medical history and/or physical examination . Have recent close contact person active TB , contact , refer physician specialize TB undergo additional evaluation , warrant , receive appropriate treatment latent TB prior simultaneously first administration study agent . Within 1 month prior first administration study agent , negative QuantiFERONTB Gold test result , newly identify positive QuantiFERONTB Gold test result active TB rule appropriate treatment latent TB initiate either prior simultaneously first administration study agent . The QuantiFERONTB Gold test require screening subject history latent TB ongoing treatment latent TB documentation complete adequate treatment describe ; Subjects documentation complete adequate treatment describe require initiate additional treatment latent TB . Have chest radiograph posterioranterior lateral view , take within 3 month prior first administration study agent read qualified radiologist , evidence current , active TB old , inactive TB . 7 . Subject meet concomitant medication requirement agree complete washout restrict medication prior start study . Washout Period : Must initiate changed medication could affect psoriasis ( e.g . beta blocker , lithium salt , antimalarial ) within 4 week period prior Week 0 study Subjects must receive immunosuppressive , chemotherapy and/or systemic therapy include oral calcineurin inhibitor ( cyclosporine ) , retinoids ( Vitamin A analogue ) , Methotrexate , Azathioprine , 6thioguanine , Mycophenolate mofetil ( MMF ) , Hydroxyurea , cytokine ( interferongamma ) within 4 week period prior Week 0 study Subjects must receive phototherapy ( broadband narrowband UVB ) within 2 week period prior Week 0 study . Subjects must receive photochemotherapy ( PUVA ) within 4 week period prior week 0 study Subjects must receive TNFα inhibitor ( infliximab , etanercept , adalimumab ) within 12 week period prior Week 0 study Subjects must receive alefacept within 12 week period prior Week 0 study . Subjects must receive ustekinumab within 12 week period prior Week 0 study . Subjects must receive treatment investigational drug within previous 4 week 5 halflives prior Week 0 ( whichever longer ) participation another clinical trial within 4 week period prior Week 0 study 1 . Subject young 18 year age . 2 . Subject le 10 % body surface involvement his/her psoriasis . 3 . Subjects erythrodermic , pustular , guttate psoriasis 4 . History know suspect intolerance ingredient investigational study product . 5 . Evidence skin condition psoriasis would interfere studyrelated evaluation psoriasis . 6 . Evidence active infection fever , chill , sweat , history untreated Lyme disease active severe infection within 4 week screen visit , screen Week 0 visit 7 . Subject history listeriosis , untreated TB , persistent active infection require hospitalization treatment IV antibiotic , IV antiretrovirals , IV antifungal within 30 day baseline , oral antibiotic , antiviral , antifungal purpose treat infection , within 14 day baseline . 8 . Have history latent active granulomatous infection , include histoplasmosis coccidioidomycosis , prior screen . 9 . Refer inclusion criterion information regard eligibility history latent TB . 10 . Have Bacille CalmetteGuerin ( BCG ) vaccination within 12 month screen . 11 . Have chest radiograph within 3 month prior first administration study agent show abnormality suggestive malignancy current active infection , include TB . 12 . Have nontuberculous mycobacterial infection opportunistic infection ( eg . Cytomegalovirus , pneumocystosis , aspergillosis ) within 6 month prior screen . 13 . History immune compromise status [ e.g . human immunodeficiency virus ( HIV ) positive status immune suppress drug ] congenital acquire immunodeficiency subject test positive HIV , Hepatitis B , and/or Hepatitis C screening procedure . 14 . Subject poorly control medical condition include , limited , unstable cardiovascular disease , poorly control diabetes , recent stroke , history recurrent infection , condition , opinion investigator , participation study would place subject risk 15 . Subject history ongoing drug alcohol abuse 16 . Subject willing comply washout requirement ( see ) 17 . Subject know , suspect unable comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Moderate severe psoriasis</keyword>
</DOC>